Value proposition

Embrace Life / Biologics that are more approachable / Pharmaceuticals reinnovated
/ Pioneering into the future

A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.





To research, development, and manufacture of both biosimilars and new biopharmaceutical products, with a commitment of contributing to the promotion of human health and social welfare.